Blood biomarkers for differential diagnosis and early detection of pancreatic cancer

被引：51

作者：

Al-Shaheri, Fawaz N. ^{[1
,2
]}

Alhamdani, Mohamed S. S. ^{[1
]}

Bauer, Andrea S. ^{[1
]}

Giese, Nathalia ^{[3
]}

Buechler, Markus W. ^{[3
]}

Hackert, Thilo ^{[3
]}

Hoheisel, Joerg D. ^{[1
]}

机构：

[1] German Canc Res Ctr, Div Funct Genome Anal, B070,Neuenheimer Feld 580, D-69120 Heidelberg, Germany

[2] Heidelberg Univ, Med Fac Heidelberg, Neuenheimer Feld 672, D-69120 Heidelberg, Germany

[3] Univ Hosp Heidelberg, Dept Gen Surg, Neuenheimer Feld 420, D-69120 Heidelberg, Germany

来源：

CANCER TREATMENT REVIEWS | 2021年 / 96卷

关键词：

Pancreatic cancer; Liquid biopsy; Blood-based biomarkers; Proteins; microRNAs; Circulating tumor DNA (ctDNA); Circulating tumor cells; Differential diagnosis; Early detection; CIRCULATING TUMOR-CELLS; AUTOIMMUNE PANCREATITIS; SERUM BIOMARKER; FREE DNA; DUCTAL ADENOCARCINOMA; CLINICAL-SIGNIFICANCE; MICRORNA SIGNATURE; MASS-SPECTROMETRY; PLASMA BIOMARKER; PROTEIN;

D O I：

10.1016/j.ctrv.2021.102193

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Pancreatic cancer is currently the most lethal tumor entity and case numbers are rising. It will soon be the second most frequent cause of cancer-related death in the Western world. Mortality is close to incidence and patient survival after diagnosis stands at about five months. Blood-based diagnostics could be one crucial factor for improving this dismal situation and is at a stage that could make this possible. Here, we are reviewing the current state of affairs with its problems and promises, looking at various molecule types. Reported results are evaluated in the overall context. Also, we are proposing steps toward clinical utility that should advance the development toward clinical application by improving biomarker quality but also by defining distinct clinical objectives and the respective diagnostic accuracies required to achieve them. Many of the discussed points and conclusions are highly relevant to other solid tumors, too.

引用

页数：16

共 171 条

[91] Soluble iC3b as an Early Marker for Pancreatic Adenocarcinoma Is Superior to CA19.9 and Radiology [J].

Maerten, Angela ;

Buechler, Markus W. ;

Werft, Wiebke ;

Wente, Moritz N. ;

Kirschfink, Michael ;

Schmidt, Jan .

JOURNAL OF IMMUNOTHERAPY, 2010, 33 (02) :219-224

[92] SST gene hypermethylation acts as a pan-cancer marker for pancreatic ductal adenocarcinoma and multiple other tumors: toward its use for blood-based diagnosis [J].

Manoochehri, Mehdi ;

Wu, Yenan ;

Giese, Nathalia A. ;

Strobel, Oliver ;

Kutschmann, Stefanie ;

Haller, Florian ;

Hoheisel, Joerg D. ;

Moskalev, Evgeny A. ;

Hackert, Thilo ;

Bauer, Andrea S. .

MOLECULAR ONCOLOGY, 2020, 14 (06) :1252-1267

[93] Discovery of Pancreatic Adenocarcinoma Biomarkers by Untargeted Metabolomics [J].

Martin-Blazquez, Ariadna ;

Jimenez-Luna, Cristina ;

Diaz, Caridad ;

Martinez-Galan, Joaquina ;

Prados, Jose ;

Vicente, Francisca ;

Melguizo, Consolacion ;

Genilloud, Olga ;

Perez del Palacio, Jose ;

Caba, Octavio .

CANCERS, 2020, 12 (04)

[94] Circulating Tumor Cells in Pancreatic Cancer: Current Perspectives [J].

Martini, Verena ;

Timme-Bronsert, Sylvia ;

Fichtner-Feigl, Stefan ;

Hoeppner, Jens ;

Kulemann, Birte .

CANCERS, 2019, 11 (11)

[95] Applications of liquid biopsies for cancer [J].

Mattox, Austin K. ;

Bettegowda, Chetan ;

Zhou, Shibin ;

Papadopoulos, Nickolas ;

Kinzler, Kenneth W. ;

Vogelstein, Bert .

SCIENCE TRANSLATIONAL MEDICINE, 2019, 11 (507)

[96] Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis [J].

Mayerle, Julia ;

Kalthoff, Holger ;

Reszka, Regina ;

Kamlage, Beate ;

Peter, Erik ;

Schniewind, Bodo ;

Maldonado, Sandra Gonzalez ;

Pilarsky, Christian ;

Heidecke, Claus-Dieter ;

Schatz, Philipp ;

Distler, Marius ;

Scheiber, Jonas A. ;

Mahajan, Ujjwal M. ;

Weiss, F. Ulrich ;

Gruetzmann, Robert ;

Lerch, Markus M. .

GUT, 2018, 67 (01) :128-137

[97] Elevation of circulating branched-chain amino acids is an early event in human pancreatic adenocarcinoma development [J].

Mayers, Jared R. ;

Wu, Chen ;

Clish, Clary B. ;

Kraft, Peter ;

Torrence, Margaret E. ;

Fiske, Brian P. ;

Yuan, Chen ;

Bao, Ying ;

Townsend, Mary K. ;

Tworoger, Shelley S. ;

Davidson, Shawn M. ;

Papagiannakopoulos, Thales ;

Yang, Annan ;

Dayton, Talya L. ;

Ogino, Shuji ;

Stampfer, Meir J. ;

Giovannucci, Edward L. ;

Qian, Zhi Rong ;

Rubinson, Douglas A. ;

Ma, Jing ;

Sesso, Howard D. ;

Gaziano, John M. ;

Cochrane, Barbara B. ;

Liu, Simin ;

Wactawski-Wende, Jean ;

Manson, Joann E. ;

Pollak, Michael N. ;

Kimmelman, Alec C. ;

Souza, Amanda ;

Pierce, Kerry ;

Wang, Thomas J. ;

Gerszten, Robert E. ;

Fuchs, Charles S. ;

Vander Heiden, Matthew G. ;

Wolpin, Brian M. .

NATURE MEDICINE, 2014, 20 (10) :1193-1198

[98] Shining new light on mammalian diving physiology using wearable near-infrared spectroscopy [J].

McKnight, J. Chris ;

Bennett, Kimberley A. ;

Bronkhorst, Mathijs ;

Russell, Debbie J. F. ;

Balfour, Steve ;

Milne, Ryan ;

Bivins, Matt ;

Moss, Simon E. W. ;

Colier, Willy ;

Hall, Ailsa J. ;

Thompson, Dave .

PLOS BIOLOGY, 2019, 17 (06)

[99] Metabolomic biomarkers of pancreatic cancer - a meta-analysis study [J].

Mehta, Khyati Y. ;

Wu, Hung-Jen ;

Menon, Smrithi S. ;

Fallah, Yassi ;

Zhong, Xiaogang ;

Rizk, Nasser ;

Unger, Keith ;

Mapstone, Mark ;

Fiandaca, Massimo S. ;

Federoff, Howard J. ;

Cheema, Amrita K. .

ONCOTARGET, 2017, 8 (40) :68899-68915

[100]

MELLBY LD, 2018, J CLIN ONCOL

← 5 6 7 8 9 10 11 12 13 14 →